Mylan: Brand/Generic Distinction Disintegration Is Necessary
This article was originally published in The Pink Sheet Daily
Executive Summary
Consolidation in the generic industry is good and necessary, Mylan CEO Heather Bresch said during a recent investor presentation. Mylan is well-positioned in the changing market, she said, thanks to business development such as its biosimilars agreements with Biocon and its Japan collaboration with Pfizer.